Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare the efficacy and safety of a single dose of a lidocaine 8 mg + cetylpyridimium chloride (CPC) 2 mg lozenge with a single dose of a lidocaine 1 mg + CPC 2 mg lozenge in the treatment of sore throat due to a common cold.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Cetylpyridinium; Lidocaine

Criteria

Inclusion Criteria:

• Patients with sore throat due to an upper respiratory tract infection, with recent onset (within 48 hours)

• Sore throat of at least moderate pain intensity

Exclusion Criteria:

• - History of hypersensitivity to any of the study drugs and listed excipients or to drugs of similar chemical classes

• Evidence of mouth breathing or severe coughing

• Evidence of overt oropharyngeal bacterial or fungal infection or evidence of lower respirator tract infection

• Severe renal, liver or cardiac impairment

• Severe lung disease